Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1669.4 Billion | 1488.34 Billion | 1343.55 Billion | 1303 Billion | 1079.33 Billion | 956.21 Billion |
| Cost of Revenue | 1014.05 Billion | 945.7 Billion | 847.74 Billion | 813.86 Billion | 675.05 Billion | 575.81 Billion |
| Gross Profit | 655.34 Billion | 542.63 Billion | 495.81 Billion | 489.13 Billion | 404.27 Billion | 380.4 Billion |
| Operating Expenses | 408.65 Billion | 432.73 Billion | 401.05 Billion | 365.2 Billion | 329.7 Billion | 304.66 Billion |
| Selling, General and Administrative Expenses | 131.37 Billion | 116.45 Billion | 102.71 Billion | 91.36 Billion | 98.72 Billion | 117.15 Billion |
| Research and Development Expenses | 140.23 Billion | 176.32 Billion | 163.27 Billion | 146.66 Billion | 98.62 Billion | 77.03 Billion |
| Other Expenses | 143.99 Billion | 139.95 Billion | 135.06 Billion | 127.17 Billion | 132.35 Billion | -3.98 Billion |
| Cost and Expenses | 1422.71 Billion | 1378.43 Billion | 1248.8 Billion | 1179.06 Billion | 1004.76 Billion | 880.47 Billion |
| Operating Income | 246.59 Billion | 109.9 Billion | 94.75 Billion | 123.93 Billion | 74.57 Billion | 75.73 Billion |
| Interest Expense | 9.27 Billion | 6.84 Billion | 4.02 Billion | 3.87 Billion | 3.15 Billion | 2.71 Billion |
| Income Tax Expense | 27.99 Billion | 17.18 Billion | 38.23 Billion | 31.43 Billion | 18.84 Billion | 26.63 Billion |
| Earnings before Tax | 241.59 Billion | 97.16 Billion | 80.59 Billion | 121.83 Billion | 71.82 Billion | 68.34 Billion |
| Net Income | 212.52 Billion | 80.95 Billion | 42.72 Billion | 91.63 Billion | 53.88 Billion | 42.39 Billion |
| Earnings Per Share Basic | 16.7 Thousand | 6608.77 | 3434.22 | 7317.59 | 4300.43 | 3382.95 |
| Earnings Per Share Diluted | 16.7 Thousand | 6608.77 | 3434.22 | 7317.59 | 4300.43 | 3382.95 |
| Weighted Average Shares Outstanding | 12.72 Million | 12.24 Million | 12.43 Million | 12.52 Million | 12.52 Million | 12.53 Million |
| Weighted Average Shares Outstanding (Diluted) | 12.72 Million | 12.24 Million | 12.43 Million | 12.52 Million | 12.52 Million | 12.53 Million |
| Gross Margin | 0.39 | 0.36 | 0.37 | 0.38 | 0.37 | 0.40 |
| EBIT Margin | 0.17 | 0.10 | 0.08 | 0.12 | 0.09 | 0.10 |
| Profit Margin | 0.13 | 0.05 | 0.03 | 0.07 | 0.05 | 0.04 |
| EBITDA | 283.62 Billion | 143.5 Billion | 112.61 Billion | 149.39 Billion | 97.92 Billion | 92.18 Billion |
| Earnings Before Tax Margin | 0.15 | 0.07 | 0.07 | 0.10 | 0.07 | 0.08 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 396.8 Billion | 353.45 Billion | 504.61 Billion | 1669.4 Billion | 403.6 Billion | 396 Billion |
| Cost of Revenue | 257.87 Billion | 230.77 Billion | 273.76 Billion | 1014.05 Billion | 253.78 Billion | 251.65 Billion |
| Gross Profit | 138.92 Billion | 122.67 Billion | 230.84 Billion | 655.34 Billion | 149.82 Billion | 144.34 Billion |
| Operating Expenses | 103.06 Billion | 326.69 Billion | 116.45 Billion | 408.65 Billion | -94.09 Billion | -99.34 Billion |
| Selling, General and Administrative Expenses | 66.87 Billion | 66.44 Billion | 67.94 Billion | - | 94.09 Billion | 99.34 Billion |
| Research and Development Expenses | 33.13 Billion | 29.66 Billion | 45.76 Billion | - | 27.06 Billion | 31.58 Billion |
| Other Expenses | -3.05 Billion | -326.69 Billion | -2.74 Billion | -11.69 Billion | -188.18 Billion | -198.69 Billion |
| Cost and Expenses | 360.94 Billion | 326.69 Billion | 390.21 Billion | 1422.71 Billion | 253.78 Billion | 251.65 Billion |
| Operating Income | 35.86 Billion | 26.75 Billion | 114.39 Billion | 246.68 Billion | 55.73 Billion | 44.99 Billion |
| Interest Expense | 2 Billion | 2.07 Billion | 2.43 Billion | 9.27 Billion | 2.28 Billion | 2.28 Billion |
| Income Tax Expense | -16.37 Billion | 6.69 Billion | 22.12 Billion | 27.99 Billion | 9.03 Billion | 1.41 Billion |
| Earnings before Tax | 38.66 Billion | 31.79 Billion | 110.23 Billion | 241.4 Billion | 55.27 Billion | 44.58 Billion |
| Net Income | 53.36 Billion | 25.57 Billion | 88.25 Billion | 212.52 Billion | 45.59 Billion | 42.81 Billion |
| Earnings Per Share Basic | 4207.60 | 1972.62 | 6935.42 | - | 3575.97 | 3355.23 |
| Earnings Per Share Diluted | 4207.60 | 1972.62 | 6935.42 | - | 3575.97 | 3355.23 |
| Weighted Average Shares Outstanding | 12.68 Million | 12.72 Million | 12.72 Million | 12.72 Million | 12.75 Million | 12.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 12.68 Million | 12.72 Million | 12.72 Million | 12.72 Million | 12.75 Million | 12.76 Million |
| Gross Margin | 0.35 | 0.35 | 0.46 | 0.39 | 0.37 | 0.36 |
| EBIT Margin | 0.11 | 0.08 | 0.24 | - | 0.37 | 0.36 |
| Profit Margin | 0.13 | 0.07 | 0.17 | 0.13 | 0.11 | 0.11 |
| EBITDA | 45.37 Billion | 26.75 Billion | 123.47 Billion | - | 149.82 Billion | 144.34 Billion |
| Earnings Before Tax Margin | 0.09 | 0.08 | 0.23 | 0.15 | 0.14 | 0.11 |
9502
2505
TITC
QLYS
1904
6168